Literature DB >> 16981000

Cyclosporine short infusion and C2 monitoring in haematopoietic stem cell transplant recipients.

M P Hendriks1, N M A Blijlevens, A V M B Schattenberg, D M Burger, J P Donnelly.   

Abstract

Blood concentrations of cyclosporine A (CsA) >or=800 microg/l measured 2 h post-dosing, the C2 concentration, is necessary to obtain a maximal pharmacological effect and correlates well with transplant-related complications such as transplant rejection and toxicity. In an open crossover study CsA blood levels were measured during 24 h to generate a pharmacokinetic profile on days 1, 8 and 15 after starting CsA infusion in 21 haematopoietic allogeneic stem cell transplant recipients who were receiving intravenously CsA 3 mg/kg/day either by continuous infusion or by 2 h infusion given every 12 h. C2 levels after the 2 h infusion correlated better than C1 or C3 levels with the area under the concentration-time curve from 0 to 4 h (r2=0.62). C2 levels >or=800 microg/l were also achieved for 20 out of 24 (83%) of cases after the 2 h infusion of CsA without any increase of CsA-related toxicity but for only three of the 23 patients (13%) after continuous infusion. Therefore, we recommend CsA infusions in 2 h during transplant and perform C2 monitoring to obtain therapeutic C2 levels >or=800 microg/l.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16981000     DOI: 10.1038/sj.bmt.1705481

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  7 in total

1.  Pharmacokinetic and pharmacodynamic analysis of cyclosporine A (CsA) to find the best single time point for the monitoring and adjusting of CsA dose using twice-daily 3-h intravenous infusions in allogeneic hematopoietic stem cell transplantation.

Authors:  Tatsuo Furukawa; Tori Kurasaki-Ida; Masayoshi Masuko; Nobuhiro Tsukada; Kiyoshi Okazuka; Naoko Sato; Toshio Yano; Takashi Abe; Akihito Momoi; Yasuhiko Shibasaki; Masutaka Higashimura; Kaori Karimata; Masato Moriyama; Takashi Kuroha; Jun Takizawa; Ken Toba; Miwako Narita; Ichiro Fuse; Masuhiro Takahashi; Yoshifusa Aizawa
Journal:  Int J Hematol       Date:  2010-06-09       Impact factor: 2.490

2.  Population pharmacokinetics of ciclosporin in haematopoietic allogeneic stem cell transplantation with emphasis on limited sampling strategy.

Authors:  Abraham J Wilhelm; Peer de Graaf; Agnes I Veldkamp; Jeroen J W M Janssen; Peter C Huijgens; Eleonora L Swart
Journal:  Br J Clin Pharmacol       Date:  2012-04       Impact factor: 4.335

3.  Influence of dosing schedule on organ exposure to cyclosporin in pediatric hematopoietic stem cell transplantation: analysis with a PBPK model.

Authors:  Cécile Gérard; Nathalie Bleyzac; Pascal Girard; Gilles Freyer; Yves Bertrand; Michel Tod
Journal:  Pharm Res       Date:  2010-09-02       Impact factor: 4.200

4.  Links between cyclosporin exposure in tissues and graft-versus-host disease in pediatric bone marrow transplantation: analysis by a PBPK model.

Authors:  Cécile Gérard; Nathalie Bleyzac; Pascal Girard; Gilles Freyer; Yves Bertrand; Michel Tod
Journal:  Pharm Res       Date:  2010-10-21       Impact factor: 4.200

5.  Methotrexate dose delivery is more important than ciclosporin level in graft-versus-host disease prophylaxis following T-replete reduced-intensity sibling allogeneic stem cell transplant.

Authors:  Patrick Medd; Ian Monk; Robert Danby; Ram Malladi; Ruth Clifford; Amanda Ellis; David Roberts; Chris Hatton; Paresh Vyas; Tim Littlewood; Andy Peniket
Journal:  Int J Hematol       Date:  2011-09-07       Impact factor: 2.490

Review 6.  Pharmacokinetics, Pharmacodynamics and Pharmacogenomics of Immunosuppressants in Allogeneic Haematopoietic Cell Transplantation: Part I.

Authors:  Jeannine S McCune; Meagan J Bemer
Journal:  Clin Pharmacokinet       Date:  2016-05       Impact factor: 6.447

7.  Decreased levels of circulating IL17-producing CD161+CCR6+ T cells are associated with graft-versus-host disease after allogeneic stem cell transplantation.

Authors:  Anniek B van der Waart; Walter J F M van der Velden; Astrid G S van Halteren; Marij J L G Leenders; Ton Feuth; Nicole M A Blijlevens; Robbert van der Voort; Harry Dolstra
Journal:  PLoS One       Date:  2012-12-04       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.